• Kashmira A Date, Andrea Vicari, Terri B Hyde, Eric Mintz, M Carolina Danovaro-Holliday, Ariel Henry, Jordan W Tappero, Thierry H Roels, Joseph Abrams, Brenton T Burkholder, Cuauhtémoc Ruiz-Matus, Jon Andrus, and Vance Dietz.
• Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA. kdate@cdc.gov
• Emerging Infect. Dis. 2011 Nov 1; 17 (11): 2105-12.

AbstractOral cholera vaccines (OCVs) have been recommended in cholera-endemic settings and preemptively during outbreaks and complex emergencies. However, experience and guidelines for reactive use after an outbreak has started are limited. In 2010, after over a century without epidemic cholera, an outbreak was reported in Haiti after an earthquake. As intensive nonvaccine cholera control measures were initiated, the feasibility of OCV use was considered. We reviewed OCV characteristics and recommendations for their use and assessed global vaccine availability and capacity to implement a vaccination campaign. Real-time modeling was conducted to estimate vaccine impact. Ultimately, cholera vaccination was not implemented because of limited vaccine availability, complex logistical and operational challenges of a multidose regimen, and obstacles to conducting a campaign in a setting with population displacement and civil unrest. Use of OCVs is an option for cholera control; guidelines for their appropriate use in epidemic and emergency settings are urgently needed.

16 keywords...

hide…